Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) EBITDA (2016 - 2025)

Avalo Therapeutics filings provide 12 years of EBITDA readings, the most recent being -$13.7 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 61.25% to -$13.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$78.2 million, a 122.58% decrease, with the full-year FY2025 number at -$78.2 million, down 122.58% from a year prior.
  • EBITDA hit -$13.7 million in Q4 2025 for Avalo Therapeutics, up from -$30.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $98.5 million in Q2 2024 to a low of -$121.3 million in Q1 2024.
  • Median EBITDA over the past 5 years was -$13.4 million (2025), compared with a mean of -$13.4 million.
  • The widest YoY moves for EBITDA: up 1301.79% in 2024, down 1118.38% in 2024.
  • Avalo Therapeutics' EBITDA stood at -$18.0 million in 2021, then soared by 50.7% to -$8.9 million in 2022, then grew by 13.52% to -$7.7 million in 2023, then crashed by 361.47% to -$35.3 million in 2024, then surged by 61.25% to -$13.7 million in 2025.
  • The last three reported values for EBITDA were -$13.7 million (Q4 2025), -$30.6 million (Q3 2025), and -$20.8 million (Q2 2025) per Business Quant data.